Blueprint Medicines Corporation or Veracyte, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Biotech Firms

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Blueprint Medicines Corporation and Veracyte, Inc. have been navigating this landscape since 2014. Over the past decade, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing from approximately $7.9 million in 2014 to nearly $295 million in 2023. This represents a growth of over 3,600%. In contrast, Veracyte, Inc. has managed a more moderate increase, with expenses rising from about $40.8 million to $184.2 million, a growth of around 350%.

While both companies have expanded their SG&A budgets, Blueprint Medicines' expenses have surged at a much faster rate. This could indicate aggressive expansion strategies or higher operational costs. Investors and stakeholders should consider these trends when evaluating the companies' financial strategies and future growth potential.